Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to -$31.1 million.

  • Tango Therapeutics' Free Cash Flow rose 7.17% to -$31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$146.8 million, marking a year-over-year decrease of 19.15%. This contributed to the annual value of -$132.3 million for FY2024, which is 10.67% down from last year.
  • Tango Therapeutics' Free Cash Flow amounted to -$31.1 million in Q3 2025, which was up 16.26% from -$37.1 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Free Cash Flow registered a high of -$8.0 million during Q2 2021, and its lowest value of -$41.7 million during Q1 2025.
  • Moreover, its 3-year median value for Free Cash Flow was -$33.5 million (2024), whereas its average is -$32.9 million.
  • As far as peak fluctuations go, Tango Therapeutics' Free Cash Flow tumbled by 25,018,650.00% in 2021, and later rose by 24.62% in 2023.
  • Tango Therapeutics' Free Cash Flow (Quarterly) stood at -$17.6 million in 2021, then tumbled by 66.54% to -$29.3 million in 2022, then rose by 5.51% to -$27.7 million in 2023, then crashed by 32.78% to -$36.8 million in 2024, then grew by 7.17% to -$31.1 million in 2025.
  • Its last three reported values are -$31.1 million in Q3 2025, -$37.1 million for Q2 2025, and -$41.7 million during Q1 2025.